Placenta Market Share, Size, Trends, Industry Analysis Report, By Type (Porcine, Equine, Ovine, Others); By Application; By Region; Segment Forecast, 2023-2032
- Published Date:Apr-2023
- Pages: 116
- Format: PDF
- Report ID: PM3162
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global placenta market was valued at USD 76.26 Million in 2022 and is expected to grow at a CAGR of 12.4% during the forecast period. The market is anticipated to be driven primarily by the expanding development of precision medicine, innovations in stem cell therapy, & rise in the number of clinical studies. The rising demand for anti-aging and skin-rejuvenating remedies is also one of the major factors driving the placenta market. Due to rigorous rules and ethical concerns surrounding placenta use, the market's growth is constrained.
Know more about this report: Request for sample pages
Furthermore, new insights into the placenta's involvement in directing fetal development & metabolism have generated interest in the understanding the link between fetal & placental well-being. The main characteristics of the placenta & its derivatives, such as cellular composition, immunological & endocrine aspects, and the ability to invade & deport, are being examined. From the viewpoint that the placental material is a special source for regenerative cell therapies and a lesson for immunological tolerance, these characteristics are considered.
Some of the additional factors that support the anticipated expansion in demand for placental cells throughout the forecast period include recent developments in therapeutics and technological advancements in the market for placental utilization. For instance, according to a 2021 article by Felix R. De Bie, extreme preterm continues to be a significant contributor to infant mortality and severe long-term illness. Due to iatrogenic harm and the high prematurity of newborns, current neonatal care is linked to considerable morbidity. The guiding premise of artificial placenta and womb technologies is a more physiological one, replacing placental function and offering a womb-like environment.
The pandemic of COVID-19 had a beneficial impact on the market. Clinical trials have expanded as a result of the increased interest among medical researchers in the use of the products in the treatment of the new coronavirus. Companies and research institutions are working together to create cutting-edge disease treatments.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
Due to the rising frequency of venous illnesses and the rising number of new products being approved to meet this need, the market is anticipated to develop at a significant rate throughout the forecast period. The placenta market is expected to develop as a result of increased disease awareness, the value of early detection growing, and rising spending on chronic diseases. Additionally, the major market participants are spending money on technologically enhanced product creation and research, which will increase the use of placenta products in both developed and developing nations.
For instance, according to the Noa Sher & Racheli Ofir case study that was published in 2018 for the treatment of hematological illnesses, the PLX-R18, a placenta derived product originating from fetal cells, that are extracted from placenta, is currently being developed. Another placenta-derived cell therapy product called PLX-PAD varies from PLX-R18 in that it primarily comes from the mother, secretes much lower amounts of IL-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1), and is unable to trigger BM migration.
Report Segmentation
The market is primarily segmented based on type, application, and region.
|
By Type |
By Application |
By Region |
|
|
|
Know more about this report: Request for sample pages
Ovine segment will account for a higher share of the market during forecast period
In 2022, the Ovine dominated the whole market. The rising demand for dietary supplements, medicines, and cosmetics that contain placenta extracts is to blame for the market's expansion. Additionally, placenta therapy is now utilized to treat a number of ailments, including adrenocortical hypofunction, lumbago, weakened immunity, infertility, melancholy, inability to produce milk, hair loss, and antiaging. Although limited availability has kept human placenta treatment from being widely used up until now, conventional health practitioners are increasingly admitting its efficacy. Treatment with sheep/ Ovine placenta extract has advantages such as nourishing blood and skin, sedative effects, and lengthened lifespan.
For instance, according to a research report published in 2022 by Ming Yu Chou, sheep placenta extract (SPE) is widely utilized in traditional medicine for its medicinal effects such as wound healing, antioxidant, & anti-inflammatory qualities. The impact of SPE on antiaging is still unknown, though. The study's findings show that lipid peroxidation (LPO) was reduced and catalase & super-oxide dis-mutase (SOD) activity were dramatically elevated in the brain tissues. SPE supplementation reduced the oxidative stress brought on by ageing in mice without causing toxicity and decreased the ageing index, indicating the potential of SPE as a potent antiaging remedy.
The pharmaceutical segment has the highest revenue in 2022
The pharmaceutical industry dominated the market in 2022 and is anticipated to grow at the highest CAGR both that year and over the next few years. The significant factors driving the market are an increase in clinical trials, an increase in strategic initiatives, an increase in the prevalence of chronic diseases, and improvements in healthcare services. In addition to the advantages supplied by other tissues, placental stem cells also offer additional advantages. It is simple to obtain these cells, and neither the mother nor the child is harmed. Due to this, mesenchymal stem cells are becoming more and more recognized as potent immunomodulatory that are essential to the development of new patient treatments for anti-aging.
The demand in North America is expected to witness significant growth during projected timeframe
North America is expected to expand the quickest over the forecasted period, with a predicted global revenue growth in 2022. The main factors driving the market include North America's robust biotechnology sector, the existence of major players, considerable R&D, and the promotion of personalized medications. Furthermore, due to the rising prevalence of diseases including cancer, neurological disorders, and diabetes, placenta stem cells and placenta injection are predicted to expand quickly. For instance, according to the clinical research “A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects with Diabetic Peripheral Neuropathy”, funded by the Celularity Incorporated and completed in 2022.
The prevalence of pre-eclampsia and miscarriage, two of the most prevalent illnesses of human pregnancy, is also a major reason driving this market's expansion. For these reasons, the government has increased funding for placenta research, which will further spur the development of this area. For instance, a study initiative led by the University of Adelaide will provide crucial new understanding throughout the earliest stages of human development to aid in lowering infertility and pregnancy difficulties, according to a 2022 article. This cooperative effort will investigate interactions between early placenta cells and the mother's uterus and is supported by a USD 5 million grant from the NHMCR.
Competitive Insight
Some of the major players operating in the global market include Japan Natural Laboratories Co.Ltd., Japan Bio Products Co.Ltd., BIOON, CJT, Brroklyn Placenta Services, Atlanta Placenta, MiMedx Group, Inc., TelaGen, Thimba Li, and Agri-Labco-Products.
Recent Developments
- In October, 2022, scientists in the US announced the creation of a "placenta-on-a-chip" that resembles the molecular transfer of nutrients that takes place between the mother & foetus during pregnancy. The gadget was developed by Sarah Du & its colleagues at “Florida Atlantic University” utilizing 2 microfluidic channels that were connected by a complex web of moistened fibres that were cultivated with various placental cells on each side. The set-up made it possible for the scientists to mimic the interruptions to nutrition exchange brought on by placental malaria, which may be a crucial step in the development of a cure.
Placenta Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 82.41 Million |
|
Revenue forecast in 2032 |
USD 236.01 Million |
|
CAGR |
12.40% from 2023 - 2032 |
|
Base year |
2021 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2023 to 2032 |
|
Segments covered |
By Type, By Application, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
Japan Natural Laboratories Co.Ltd., Japan Bio Products Co.Ltd., BIOON, CJT, Brroklyn Placenta Services, Atlanta Placenta, MiMedx Group, Inc., TelaGen, Thimba Li, and Agri-Labco-Products. |
FAQ's
Key companies in Placenta Market are Japan Natural Laboratories Co.Ltd., Japan Bio Products Co.Ltd., BIOON, CJT, Brroklyn Placenta Services, Atlanta Placenta, MiMedx Group, Inc., TelaGen, Thimba Li.
The global placenta market expected to grow at a CAGR of 12.4% during the forecast period.
key segments covered in Placenta Market are type, application, and region.
key driving factors in Placenta Market are technological advancement.
The global placenta market size is expected to reach USD 236.01 Million by 2032.
© 2024 Polaris Market Research and Consulting. All rights reserved
